05 August 2025
Intas Pharmaceuticals has announced the launch of Hetronifly™ (serplulimab), India’s first novel immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC).
Serplulimab is a humanized monoclonal antibody that works through a dual-blockade mechanism, targeting both PD-L1 and PD-L2 while delivering the highest PD-1 internalization. This makes it a significant breakthrough in the treatment of aggressive lung cancer.
The therapy has already been approved in nearly 40 countries, including major markets across Europe and Asia, and has benefited more than 110,000 patients worldwide. Phase 3 clinical trial results (ASTRUM-005), presented at ASCO 2025, showed encouraging survival outcomes, with a 4-year overall survival rate of 21.9% when used in combination with chemotherapy.
Intas is introducing Hetronifly™ in India at a price point around 75% lower than existing immunotherapies for the same indication, making it far more accessible to patients.
Binish Chudgar, Chairman & Managing Director of Intas Pharmaceuticals, said the launch highlights the company’s commitment to providing affordable, high-impact global therapies to patients in India.
Intas Pharmaceuticals has announced the launch of Hetronifly™ (serplulimab), India’s first novel immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC).
Serplulimab is a humanized monoclonal antibody that works through a dual-blockade mechanism, targeting both PD-L1 and PD-L2 while delivering the highest PD-1 internalization. This makes it a significant breakthrough in the treatment of aggressive lung cancer.
The therapy has already been approved in nearly 40 countries, including major markets across Europe and Asia, and has benefited more than 110,000 patients worldwide. Phase 3 clinical trial results (ASTRUM-005), presented at ASCO 2025, showed encouraging survival outcomes, with a 4-year overall survival rate of 21.9% when used in combination with chemotherapy.
Intas is introducing Hetronifly™ in India at a price point around 75% lower than existing immunotherapies for the same indication, making it far more accessible to patients.
Binish Chudgar, Chairman & Managing Director of Intas Pharmaceuticals, said the launch highlights the company’s commitment to providing affordable, high-impact global therapies to patients in India.
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.